325例新型冠状病毒肺炎患者口服类镇静催眠药物使用情况分析  

Use of Oral Sedative-Hypnotic Drugs in 325 Patients with COVID-19

作　　者：张育勤 胡婷婷 米婷婷 谭永红 ZHANG Yuqin;HU Tingting;MI Tingting;TAN Yonghong(General Hospital of Western Theater Command of PLA,Chengdu,Sichuan,China 610083)

机构地区：[1]中国人民解放军西部战区总医院,四川成都610083

出　　处：《中国药业》2022年第13期120-122,共3页China Pharmaceuticals

摘　　要：目的分析新型冠状病毒肺炎患者住院期间口服类镇静催眠药物的使用情况,为今后重大突发公共卫生事件时睡眠障碍患者的诊疗提供参考。方法回顾性分析泰康同济(武汉)医院2020年2月13日至3月12日新型冠状病毒肺炎出院患者的病历325份,统计患者的性别、年龄,以及住院期间口服类镇静催眠药物和合并抗抑郁、抗焦虑、抗精神病药物的使用情况。采用Epidata 3.1数据管理软件录入数据,采用SPSS 17.0统计学软件分析。结果325例患者中,入院时存在睡眠障碍的91例(28.00%)。其中,男35例(10.77%),女56例(17.23%),组间差异显著(χ^(2)=8.793,P<0.05);平均年龄(57.11±12.41)岁,平均患病时间(18.00±7.70)d;家庭影响、合并基础疾病、年龄、患病时间对睡眠障碍的发生均无显著影响(P>0.05)。使用口服类镇静催眠药物的122例(37.54%),以艾司唑仑(47.54%)和唑吡坦(43.44%)为主,平均药物介入干预时间为(8.06±3.94)d,平均给药疗程为(10.98±6.00)d,联用抗抑郁药物氟哌噻吨美利曲辛5例(4.10%)、抗精神病药物米氮平和奥氮平4例(3.28%)。结论对存在睡眠障碍的新型冠状病毒肺炎患者给予口服类镇静催眠药物干预,可改善其睡眠,稳定其情绪。Objective To analyze the use of oral sedative-hypnotic drugs in patients with coronavirus disease 2019(COVID-19)during hospitalization,and to provide a reference for the diagnosis and treatment of patients with sleep disorder in major public health emergencies in the future.Methods A total of 325 medical records of patients with COVID-19 discharged from the Taikang Tongji(Wuhan)Hospital from February 13 to March 12,2020 were analyzed retrospectively.The patients′gender,age,their use of oral sedative-hypnotic drugs and combined antidepressants,anxiolytics and antipsychotics during hospitalization were counted.The data were inputted by the Epidata 3.1 data management software and analyzed by the SPSS 17.0 statistical software.Results Among the 325 patients,there were 91 patients(28.00%)with sleep disorder on admission,of which there were 35 males(10.77%)and 56 females(17.23%),with a significant difference between the groups(χ^(2)=8.793,P<0.05).The average age of the 91 patients was(57.11±12.41)years old and their average duration of illness was(18.00±7.70)d.Family influence,complicated with basic diseases,age and duration of illness had no significant effect on the occurrence of sleep disorder(P>0.05).A total of 122 patients(37.54%)were treated with oral sedative-hypnotic drugs,mainly estazolam(47.54%)and zolpidem(43.44%),the average duration of intervention was(8.06±3.94)d,and the average course of administration was(10.98±6.00)d.Five patients(4.10%)were treated with oral sedative-hypnotic drugs combined with antidepressant flupentixol and melitracen,and four patients(3.28%)were treated with oral sedative-hypnotic drugs combined with antipsychotic mirtazapine and olanzapine.Conclusion The intervention of oral sedative-hypnotic drugs in COVID-19 patients with sleep disorders can improve patients′sleep and stabilize their mood.

关 键 词：新型冠状病毒肺炎 口服类镇静催眠药物 睡眠障碍 抑郁 焦虑 突发公共卫生事件 

分 类 号：R95[医药卫生—药学] R971